Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on October 10, 2017. The filing discloses a material event under Regulation FD regarding a registered direct offering of securities.
Key Financial Metrics
The filing details a capital raise with the following specific metrics:
- Gross Proceeds: Approximately $7.76 million.
- Offering Price: $1.87375 per share and related warrant.
- Common Stock Issued: Approximately 4.1 million shares.
- Warrants Issued: Approximately 3.1 million warrants.
- Warrant Exercise Price: $1.78.
- Warrant Expiration: Seven years from issuance.
The filing text does not provide clear values for revenue, profit, cash flow, margins, existing debt, or liquidity positions as this is a transactional report rather than a periodic financial statement.
Material Changes
The primary material change is the execution of securities purchase agreements with institutional investors. The offering is priced at-the-market and includes an option for investors to purchase Series B convertible preferred stock instead of common stock if the purchase would result in beneficial ownership exceeding 4.99%. The preferred stock has a conversion price of $1.87375 and no dividend rights.
Outlook, Risks, and Unusual Items
Closing Status: The offering is expected to close on or about October 12, 2017, subject to customary closing conditions.
Registration: The company has agreed to file a registration statement for the resale of shares issuable upon exercise of the Series D warrants.
Unusual Items: The filing does not disclose unusual items, risks, or management commentary beyond the mechanics of the offering.
Investor Verification Checklist
- Verify the closing of the offering on or about October 12, 2017.
- Confirm the final number of shares and warrants issued versus the approximate figures provided.
- Review the filed registration statement for the resale of warrant shares.
- Check for any subsequent filings regarding the conversion of Series B preferred stock if applicable.